top of page
  • Active, not recruiting

NCT02519452: Phase 1 - Daratumumab + Recombinant Human Hyaluronidase (rHuPH20) RRMM - PAVO Study

Updated: May 6, 2022

MMY1004 (PAVO) Study

RRMM

The purpose of the study is to evaluate the pharmacokinetics and safety from the mixture of daratumumab and rHuPH20 prepared immediately before administration via Subcutaneous (SC) delivery (Part 1) and CF (co-formulated daratumumab and rHuPH20 preparation) administration via SC delivery of daratumumab (Part 2) and to evaluate the safety of Dara-CF 1800 milligram (mg) SC delivery without pre-dose and post-dose corticosteroids (Part 3).



Drug: Daratumumab Subcutaneous (SC) Administration

Drug: Recombinant Human Hyaluronidase [rHuPH20]) SC Administration


Multiple Locations

International Study


ClinicalTrials.gov Identifier: NCT02519452


 

 

Blood; Aug 2019




 

* Daratumumab (Darzalex)

Comments


Posts Archive
bottom of page